Basic information of 50 new molecular entities approved by the FDA in 2024 SNO Trade name Active ingredient Innovator Indication Strength Dosage form 1 Alhemo concizumab-mtci For routine prophylaxis to prevent bleeding episodes in hemophilia A and B 2 Alyfterk vanzacaftor, tezacaftor, and deutivacaftor VERTEX PHARMACEUTICALS INC To treat cystic fibrosis 50 […]
API Flash News
Category: Articles
Back To Top